Tesamorelin — Research Overview
Chemical Name: Trans-3-hexenoic acid-GRF (1-44) amide Also Known As: TH9507, Tesamorelin acetate Brand Names: EGRIFTA SV (original formulation), EGRIFTA WR (F8 formulation, approved March 2025) Developer: Theratechnologies Inc. Structure: Synthetic 44-amino acid analog of the complete human growth hormone-releasing hormone (GHRH 1-44) sequence, with a trans-3-hexenoic acid (hexenoyl) moiety attached to the tyrosine residue at the amino terminus FDA Approval Status: FDA-approved since 2010 for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. A new weekly-reconstitution formulation (EGRIFTA WR) received FDA approval in March 2025. Category: GHRH analog / growth hormone secretagogue / FDA-approved biologic
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption outside of the specific FDA-approved indication described above. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of the complete 44-amino acid human growth hormone-releasing hormone sequence, making it structurally more complete than shorter GHRH analogs such as sermorelin (GHRH 1-29) or Modified GRF 1-29 (CJC-1295 No DAC). It was developed by Theratechnologies to address one of the fundamental limitations of native GHRH as a therapeutic tool — rapid enzymatic degradation in plasma by dipeptidyl peptidase-4 (DPP-4).
The critical structural modification in tesamorelin is the addition of a trans-3-hexenoic acid (hexenoyl) moiety to the tyrosine residue at the N-terminus. This hydrophobic addition renders tesamorelin resistant to DPP-4 cleavage — the primary degradation pathway for native GHRH — substantially extending its effective half-life while preserving full agonist activity at the GHRH receptor. In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency to endogenous GHRH as confirmed in FDA prescribing information.
Tesamorelin is the only member of the GHRH analog peptide class to have received FDA approval following full Phase 2 and Phase 3 randomized controlled clinical trial programs, making it the most extensively characterized and regulatory-vetted peptide in this research category. It was approved in 2010 as EGRIFTA and a new formulation (EGRIFTA WR) providing weekly rather than daily reconstitution was approved in March 2025.
Mechanism of Action
Tesamorelin stimulates growth hormone-releasing hormone receptors (GHRHR) on somatotroph cells of the anterior pituitary gland, activating the Gs protein and adenylate cyclase pathway to increase intracellular cAMP, which drives both the synthesis of new growth hormone and the pulsatile release of stored GH from secretory granules.
The resulting GH secretion occurs in a physiological pulsatile pattern rather than the sustained supraphysiological elevation associated with exogenous recombinant GH administration. This pulsatile release pattern preserves the normal IGF-1 feedback inhibition loop, which limits excessive IGF-1 accumulation and the associated side effects seen with direct GH replacement. The FDA prescribing information notes that tesamorelin produces no clinically significant changes in other pituitary hormones including TSH, LH, or ACTH, confirming selectivity for the GH axis.
The downstream effects of augmented GH secretion and the associated IGF-1 increase that are relevant to the clinical and research profile of tesamorelin include the following.
Enhanced lipolysis in visceral adipose tissue: GH preferentially drives lipolysis in visceral fat depots rather than subcutaneous fat, producing the selective reduction in visceral adipose tissue that distinguishes tesamorelin’s effects from general weight loss interventions.
Hepatic effects: IGF-1 and GH act on hepatocytes to promote fatty acid oxidation, reduce hepatic de novo lipogenesis, and modulate inflammatory and fibrotic gene expression pathways — mechanisms relevant to tesamorelin’s observed effects on liver fat and histology in clinical trials.
Lean mass preservation: GH promotes protein synthesis and nitrogen retention, contributing to the lean mass preservation and modest lean mass increases observed across clinical trials without proportional effects on subcutaneous fat.
Feedback preservation: Unlike exogenous GH administration, GHRH analog stimulation operates within the existing hypothalamic-pituitary feedback architecture. When GH and IGF-1 rise, they feedback to suppress further GHRH receptor stimulation, providing a self-limiting mechanism that prevents the excessive IGF-1 elevation and associated metabolic complications seen with supraphysiological GH exposure.
Published Research
Study 1 — Phase 3 Pivotal Trial 1: Visceral Fat Reduction in HIV-Associated Lipodystrophy
This is one of two pivotal Phase 3 randomized double-blind placebo-controlled multicenter trials that formed the basis of tesamorelin’s 2010 FDA approval. The trial enrolled 412 HIV-infected patients (86% male) with documented abdominal lipohypertrophy. Participants received tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks in the main phase followed by a 26-week extension phase.
The primary endpoint — change in visceral adipose tissue (VAT) measured by CT scan — was significantly improved in the tesamorelin group compared to placebo: a reduction of 27.8 cm2 versus an increase of 5.1 cm2 in the placebo group, representing a relative difference of 20.2% (P less than 0.001).
The ratio of visceral to subcutaneous adipose tissue (VAT:SAT) showed a relative difference of 19.8% (P less than 0.001), confirming selective effects on visceral rather than overall body fat.
Tesamorelin was generally well tolerated. Adverse events included arthralgia, peripheral edema, myalgia, and injection site reactions. IGF-1 levels rose above the upper limit of normal in some participants on tesamorelin.
Referenced in FDA NDA 22-505 and described in PMC review: https://pmc.ncbi.nlm.nih.gov/articles/PMC3218714/
Study 2 — Phase 3 Pivotal Trial 2: Concordant Visceral Fat Findings
The second pivotal Phase 3 trial enrolled 404 HIV-infected patients (84% male) and used an identical primary endpoint design. Results were concordant with Study 1.
Visceral adipose tissue was reduced by 21 cm2 in the tesamorelin group versus 1 cm2 in placebo, a relative difference of 10.3% (P less than 0.001).
VAT:SAT relative difference was 10.5% (P less than 0.001).
Both trials combined in the meta-analysis described below confirm the reproducibility and statistical robustness of these findings.
Referenced in FDA NDA 22-505 and PMC review: https://pmc.ncbi.nlm.nih.gov/articles/PMC3218714/
Study 3 — Randomized Controlled Trial: Liver Fat and Fibrosis in HIV-Associated NAFLD
Authors: Stanley TL, Fourman LT, Feldpausch MN et al. (Massachusetts General Hospital and NIH) Year: 2019 Journal: The Lancet HIV PMID: 31611038 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288/
This randomized double-blind multicenter trial was the first study to formally evaluate tesamorelin as a treatment for non-alcoholic fatty liver disease in people with HIV — a population with high NAFLD prevalence and no approved pharmacological treatments for the condition. 61 people with HIV infection and hepatic fat fraction of 5% or more were randomized 1:1 to tesamorelin 2 mg daily or identical placebo for 12 months, followed by a 6-month open-label phase.
Tesamorelin reduced hepatic fat fraction compared to placebo with an absolute effect size of 4.1% (95% CI -7.6 to -0.7, P equal to 0.02), corresponding to a 37% relative reduction (P equal to 0.02).
35% of tesamorelin recipients achieved resolution of NAFLD defined as hepatic fat fraction below 5% at 12 months, compared to 4% of the placebo group (P equal to 0.0069).
Tesamorelin recipients were significantly less likely to experience progression of fibrosis at 12 months (10% versus 37% in the placebo group, P equal to 0.044) — a clinically meaningful finding given that fibrosis stage is the most important predictor of mortality in people with NAFLD.
There were no significant differences in fasting glucose, liver enzymes, lipids, or CD4 count between groups, demonstrating a favorable metabolic safety profile in this study.
The authors concluded that tesamorelin might be beneficial in people with HIV and NAFLD, and further studies are needed to determine long-term histological effects. This was the first strategy shown to be effective against NAFLD in the HIV population.
Study 4 — Hepatic Transcriptomic Mechanism Analysis
Authors: Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN et al. (Massachusetts General Hospital, Harvard, Broad Institute, NIH) Year: 2020 Journal: JCI Insight PMID: 32701508 Full text: https://insight.jci.org/articles/view/140134
This study leveraged paired liver biopsy specimens from the Lancet HIV NAFLD trial to characterize the hepatic gene expression changes underlying tesamorelin’s clinical effects, using gene set enrichment analysis (GSEA) on transcriptomic data from liver tissue.
Tesamorelin increased hepatic expression of gene sets involved in oxidative phosphorylation, suggesting improved mitochondrial energy metabolism in liver tissue.
Tesamorelin decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division — consistent with a reduction in the inflammatory and fibrotic activity that drives NAFLD progression.
Tesamorelin reciprocally upregulated gene sets associated with favorable hepatocellular carcinoma prognosis and downregulated gene sets associated with poor prognosis, providing a molecular basis for the anti-fibrotic effects observed clinically.
Changes in hepatic gene expression correlated with improved fibrosis-related gene scores in tesamorelin-treated participants, linking the transcriptomic findings to the clinical fibrosis outcomes from the parent trial.
The authors concluded that these findings inform understanding of pulsatile GH action on the liver and provide a mechanistic basis for the observed clinical effects of tesamorelin on liver disease.
Study 5 — Meta-Analysis of Randomized Controlled Trials: Body Composition, Hepatic Fat, and Safety
Authors: Published in ScienceDirect Year: 2026 Journal: Diabetes and Metabolic Syndrome: Clinical Research and Reviews Full text: https://www.sciencedirect.com/science/article/abs/pii/S1871403X26000025
This systematic review and random-effects meta-analysis searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 and included five randomized controlled trials evaluating tesamorelin versus placebo in adults with HIV. Risk of bias was assessed using RoB 2.0 and evidence certainty using GRADE methodology.
Tesamorelin was associated with significant reduction in visceral adipose tissue (mean difference -27.71 cm2, 95% CI -38.37 to -17.06, P less than 0.001).
Trunk fat was significantly reduced (mean difference -1.18 kg, 95% CI -1.40 to -0.96).
Tesamorelin also significantly reduced hepatic fat, increased lean body mass, and reduced waist circumference across included trials.
These selective effects on central adiposity were achieved without worsening glycemic parameters or lipid profiles and without increasing the risk of serious adverse events.
The authors concluded that tesamorelin is an effective and targeted therapy for HIV-associated lipodystrophy with an overall well-defined safety profile, representing an effective and relatively safe approach to address the metabolic and body composition complications of the condition.
FDA Approval Status and Regulatory Context
Tesamorelin is the only peptide in the GHRH analog class to have received FDA approval. Its regulatory history is as follows.
2010: FDA approved tesamorelin (EGRIFTA) for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy following two Phase 3 pivotal trials.
2019: Tesamorelin received approval for a new 2 mg/vial formulation (EGRIFTA SV) with simplified reconstitution.
March 2025: FDA approved EGRIFTA WR (the F8 formulation, 11.6 mg/vial), which allows weekly reconstitution rather than daily reconstitution, improving patient convenience. The new formulation maintains bioequivalence to the original and requires less than half the injection volume.
The FDA-approved indication is specifically for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The FDA has specified that tesamorelin is not indicated for weight loss management, has not been shown to help with antiretroviral therapy adherence, and that long-term cardiovascular safety has not been established.
Off-label research and clinical use in non-HIV populations exists and is legally permissible in medical settings, but is not part of the approved indication and requires individual clinical evaluation.
Adverse Effects and Safety Context
The adverse effect profile of tesamorelin is well-characterized through Phase 3 clinical trial data and post-marketing experience. Reported adverse events include arthralgia (joint pain), injection site reactions, pain in extremities, peripheral edema, and myalgia. IGF-1 levels may rise above the upper limit of normal in some patients and should be monitored. An increased risk of diabetes or impaired glucose tolerance has been observed in clinical trials relative to placebo, consistent with the known effects of GH excess on insulin sensitivity. Tesamorelin is contraindicated in active malignancy, in patients with pituitary gland tumors or prior pituitary surgery, and in pregnancy due to animal developmental toxicity data.
Current Research Status
Tesamorelin holds the distinction of being the only FDA-approved peptide in the GHRH analog class, making it unique among the compounds in this research database. Its efficacy for visceral fat reduction in HIV-associated lipodystrophy is established by multiple randomized controlled trials and a 2026 meta-analysis.
Active areas of ongoing research include NAFLD and MASLD treatment in HIV and non-HIV populations, with a prospective Phase 2 trial specifically in NAFLD patients registered at ClinicalTrials.gov (NCT03375788), muscle quality and frailty in aging populations with HIV, cardiometabolic risk reduction through visceral fat lowering, and cognitive effects of GH axis restoration.
The following remain areas of active investigation or unresolved questions:
Long-term cardiovascular safety — explicitly noted by the FDA as unestablished.
Effects in non-HIV populations as an off-label application.
Long-term liver histology outcomes beyond the 12-month NAFLD trial window.
Durability of visceral fat reduction after treatment cessation — current data confirms that VAT returns toward baseline when tesamorelin is discontinued, suggesting ongoing treatment is required to maintain effects.
Reconstitution Note
Tesamorelin is a peptide compound. Bacteriostatic water is the standard reconstitution solvent for this compound in laboratory research settings. Always confirm the recommended solvent against the specific lot datasheet before reconstitution. Note that the approved pharmaceutical formulations (EGRIFTA SV and EGRIFTA WR) have specific reconstitution instructions from the manufacturer that may differ from general laboratory peptide handling guidelines.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Tesamorelin product page: https://roguecompounds.com/product/tesamorelin/